JPW 0590

### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of

Docket No: Q90951

Hideaki SHIMADA, et al.

Appln. No.: 10/554,026

Group Art Unit: Unassigned

Confirmation No.: 1874

Examiner: Unassigned

Filed: October 21, 2005

For:

APOPTOSIS-INDUCING AGENT AND METHOD FOR INDUCING APOPTOSIS

#### SUBMISSION OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT (IPER)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For the Examiner's convenience, enclosed herewith is a copy of the International Preliminary Examination Report (IPER). It is noted that all of the references identified in the IPER were previously listed on a PTO/SB/08 A & B when a copy of the International Search Report was submitted on October 21, 2005.

Respectfully submitted,

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373

CUSTOMER NUMBER

Date: June 29, 2006

John T. Callahan

Registration No. 32,607

RECEIVED

with thanks

#### From the INTERNATIONAL BUREAU

#### PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

HIRAKI, Yusuke
Kamiya-cho MT Building, 19F, 3-20
Toranomon 4-chome
Minato-ku Tokyo 105-0001
JAPON

MAR. 3 0. 2006

Date of mailing (dayhnonth/year)
09 March 2006 (09.03.2006)

Applicant's or agent's file reference
PH-2082-PCT

International application No. PCT/JP2004/004516

IMPORTANT NOTIFICATION

International filing date (day/month/year) 30 March 2004 (30.03.2004)

Applicant

JAPAN SCIENCE AND TECHNOLOGY AGENCY et al

1. Transmittal of the translation to the applica
--

The l	International Bureau transmits herewith a copy of	f the English translation of t	he international preliminary report	011
pater	ntability (Chapter I).			

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer

Yoshiko Kuwahara

Facsimile No.+41 22 338 90 90

Facsimile No.+41 22 740 14 35

#### PATENT COOPERATION TREATY

# **PCT**

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference PH-2082-PCT	FOR FURTHER ACTION	See item 4 helow	
International application No. PCT/JP2004/004516	International filing date (day/month/year) 30 March 2004 (30.03.2004)	Priority date (day/month/year) 21 April 2003 (21.04.2003)	
International Patent Classification (8th See relevant information in Form F	n edition unless older edition indicated) PCT/ISA/237		
Applicant JAPAN SCIENCE AND TECHNOL	OGY AGENCY		

1	l. Th Int	is interi ernation	national preliminary rep nal Searching Authority	oort on patentability (Chapte under Rule 44 bis.1(a).	r I) is issued by the International Bureau on behalf of the
				of 7 sheets, including this co	over sheet. the International Searching Authority should be read as a reference
	to	the inte	rnational preliminary re	port on patentability (Chapte	er I) instead.
3	3. Th	is repor	t contains indications re	elating to the following item	s:
		$\boxtimes$	Box No. I	Basis of the report	
			Box No. Π	Priority	
		$\boxtimes$	Box No. III	Non-establishment of opin applicability	tion with regard to novelty, inventive step and industrial
			Box No. IV	Lack of unity of invention	
		$\boxtimes$	Box No. V	Reasoned statement under applicability; citations and	Article 35(2) with regard to novelty, inventive step or industrial explanations supporting such statement
		$\boxtimes$	Box No. VI	Certain documents cited	
			Βοχ Νο. VΠ	Certain defects in the inter	national application
		$\boxtimes$	Βοχ Νο. ΥΠΙ	Certain observations on th	e international application
4	not	, excep	ational Bureau will cont where the applicant m. 44bis .2).	nmunicate this report to desi akes an express request und	gnated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but er Article 23(2), before the expiration of 30 months from the priority
					Date of issuance of this report 02 March 2006 (02.03.2006)
					Authorized officer

Yoshiko Kuwahara

Telephone No. +41 22 338 90 90

The International Bureau of WIPO 34, chemin des Colombettes

1211 Geneva 20, Switzerland

#### PATENT COOPERATION TREATY

From th		NAL SEARCHI	NG AUTHOR	ITY		an.	
l'o:						PCT Talkat	On
						RITTEN OPINION OF THE IONAL SEARCHING AUTHORITY	
						(PCT Rule 43his.1)	
			`		Date of mailing (day/month/year)		
• •		igent's file referei	nce		FOR FURTHER	ACTION See paragraph 2 below	
		plication No.		International filing date	(day/month/year)	Priority date (day/month/year)	
		2004/004	516	30.03.2004	(au), memoriter,	21.04.2003	
Internat	ional Pa	tent Classification	on (IPC) or both	national classification ar	nd IPC		-
Applica <b>JAP</b>		SCIENCE	AND TEC	CHNOLOGY AGE	NCY		
1.	This o	Box No. I  Box No. II  Box No. II	Basis of the			ve step and industrial applicability	
		Box No. IV		y of invention	gard to novery, inverin	te step and moderna approaching	
	$\overline{\boxtimes}$	Box No. V	Reasoned sta	•		ovelty, inventive step or industrial	
	$\boxtimes$	Box No. VI	Certain docu	•	suppose in grand		
		Box No. VII	Cenain defec	ets in the international app	plication		
	$\boxtimes$	Box No. VIII	Certain obser	rvations on the internation	nal application		1
2.		HER ACTION	national prelin	inary examination is m	ade. this opinion will	be considered to be a written opinion o	f the
	Internathan th	itional Preliminai his one to be the	ry Examining A IPEA and the c	authority ("IPEA") excep	t that this does not appl the International Bure	y where the applicant chooses an Authority au under Rule 66. Ibis(b) that written opinio	other
	written	reply together,	where appropr	considered to be a writte riate, with amendments, of 22 months from the pri	before the expiration	the applicant is invited to submit to the IPI of 3 months from the date of mailing of I spires later.	EA a Form
	For fur	ther options, see	Form PCT/ISA	/220.			
3.	For fur	ther details, see r	notes to Form P	CT/ISA/220.			
			1C A (12)		L A corporation of the corporation		=
Name an	id mailin	ng address of the	ISA/IP		Authorized officer		
,	- 51				Talanhona No		}

International application No.
PCT/JP2004/004516

Во	ox No. 1 Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
	This opinion has been established on the basis of a translation from the original language into the following language
	, which is the language of a translation furnished for the purposes of international search (under
	Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
!	a. type of material
	a sequence listing
	table(s) related to the sequence listing
	b. format of material
	in written format
	in computer readable form
	c. time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:
	·
	· · · · · · · · · · · · · · · · · · ·
	!
	· · · · · · · · · · · · · · · · · · ·

International application No.

PCT/JP2004/004516

Box No. 1	Non-establishment of opinion	on with regard to novelty, inventive step and industrial applicability
The quest	ions whether the claimed invention a have not been examined in respect of:	appears to be novel, to involve an inventive step (to be non obvious), or to be industrially
	the entire international application	
$\boxtimes$	claims Nos. 8-14	·
becaus		
$\boxtimes$	the said international application, or t	he said claims Nos. 8-14
	relate to the following subject matter	which does not require an international preliminary examination (specify):
	Claims 8-14 relate	to methods for treatment of the human body by therapy.
		·
	the description, claims or drawings (iii are so unclear that no meaningful opin	ndicate particular elements below) or said claims Nos.
	are so uncreat that no meaning to oph	non code oc to med (speedy).
	•	
	the claims, or said claims Nos.	are so inadequately supported
لـــا	by the description that no meaningful	
$\boxtimes$		n established for said claims Nos. 8–14
	the nucleotide and/or amino acid sequinstructions in that:	nence listing does not comply with the standard provided for in Annex C of the Administrative
	the written form	has not been furnished .
		does not comply with the standard
	the computer readable form	has not been furnished
		does not comply with the standard
	the tables related to the nucleotide ar technical requirements provided for in	nd/or amino acid sequence listing, if in computer readable form only, do not comply with the a Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further detail	nils.

International application No.
. PCT/JP2004/004516

Box			ule 43bis.1(a)(i) with regard to novelty, inventive step or industrial a pporting such statement	pplicability;
1.	Statement .		*	
	Novelty (N)	Claims	1-7	YES
		Claims		NO
	Inventive step (IS)	Claims	1-7	YES
		Claims		NO
	Industrial applicability (IA)	Claims	1-7	YES
		Claims		NO

2. Citations and explanations:

#### Claims 1-7

Document 1: (J. Liu, et al.), Mol Cell, February 2000, 5 (2): 331-341

Document 2: (J. Liu, et al.), Cell, 9 February, 2001 (09.02.01), 104 (3): 353-363

Document 3: (L. He, et al.), EMBO J., 1 March, 2000 (01.03.00), 19 (5): 1034-1044

None of the documents cited in the ISR describes or suggests that FIR (FUSE binding protein interacting repressor) has an effect of inducing apoptosis.

International application No.

PCT/JP2004/004516

x No. VI	Certain docum							
Cenain	published documents	(Rule 43)	bis. I and 7	70.10)				
	Application Patent N	o.			ication date (month/year)	Filin (day/mo	g date nth/year)	Priority date (valid of day/month/year
W	0 2004/018679	A1 [E	:, x]	04.0	3.2004	22.08	.2003	23.08.20
W	0 2004/027061	A1 [E	, Y]	01.0	04.2004	16.09	.2003	17.09.20
			٠					
		٠			·			
								•
					•			
	,							
Non-writ	iten disclosures (Rule	43 <i>his</i> .1 as	nd 70.9)	<del> </del>		<del>-</del>		
Non-writ	iten disclosures (Rule Kind of non-writte			Date	c of non-written dis (day/month/year;		referring	of written disclosure to non-written disclosur day/month/year)
Non-writ				Date			referring	to non-written disclosure
Non-writ				Date			referring	to non-written disclosure
Non-writ				Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte			Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-wri	Kind of non-writte			Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)
Non-writ	Kind of non-writte	n disclosu		Date			referring	to non-wriπen disclosur iday/πιοπth/year)

International application No.

PCT/JP2004/004516

Box No. VIII

Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

#### Claims 1, 3 and 5-7

The subject matters of claims 1, 3 and 5-7 relate to an apoptosis-inducing agent having as the active ingredient a protein defined by a desired property as "interacts with FUSE binding proteins". Claims 1, 3 and 5-7 encompass all the proteins that have such property, however, only a limited part of the claimed proteins are disclosed in the sense of PCT Article 5. Therefore, the claims are not supported by the disclosure in the specification in the sense of PCT Article 6.

Even with the common technical knowledge prevailing at the time of filing of the present application, it would have been impossible to define a range of proteins that "interact with FUSE binding proteins". Accordingly, claims 1, 3 and 5-7 do not satisfy the requirement of clarity according to the provisions of PCT Article 6.